|[Frontiers in Bioscience 2, d232-241, June 1, 1997]|
MODULATION OF ARA-C INDUCED APOPTOSIS IN LEUKAMAIA BY THE PKC ACTIVATOR BRYOSTATIN 1|
Division of hermatology , Department of Pharmacology and Microbiology , Medical College of Virginia
Received 5/23/97; Accepted 5/28/97
The completion of phase I trials of bryostatin 1
(39-41) has set the stage for the development of successor studies
in which bryostatin 1 and related compounds will be combined with
other agents, based upon their ability to facilitate apoptosis.
For example, the PKC inhibitor safingol has recently been reported
to enhance mitomycin C-induced apoptosis in gastric cancer cells
(111). This suggests that interruption of the PKC pathway, either
by down-regulation or direct inhibition, may promote apoptosis
in tumors of epithelial cell origin, and in response to agents
other than ara-C.